Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries is an Israel-based global pharmaceutical company headquartered in Tel Aviv. Founded in 1901. Revenue of USD 17.3 billion in 2025, with 35,000+ employees across 48 manufacturing sites in 26 countries, producing 76 billion tablets and capsules annually.

Business Overview

Teva Pharmaceutical Industries stands as the undisputed global leader in generic pharmaceuticals, operating the most extensive generic drug manufacturing network on the planet. The company's 48 manufacturing facilities span 26 countries, with key production hubs in Israel, Hungary, Croatia, India, and the United States. This distributed network produces an extraordinary 76 billion tablets and capsules each year — a throughput that no other pharmaceutical manufacturer comes close to matching. Teva's products reach virtually every public healthcare system and community pharmacy globally, making it the backbone of affordable medicine access worldwide.

Under CEO Richard Francis's "Pivot to Growth" strategy, Teva has successfully transformed from a debt-burdened generics giant into a dual-focus company pairing unmatched generic manufacturing scale with a rapidly growing innovative medicines portfolio. The innovative drug franchise, anchored by Austedo (Huntington's disease/tardive dyskinesia), Ajovy (migraine prevention), and Uzedy (schizophrenia), has surpassed USD 3 billion in combined revenue, effectively offsetting generic pricing headwinds. The company's 2025 results marked its third consecutive year of growth, with the innovative portfolio delivering its 11th consecutive quarter of expansion.

Key Strengths

First, Teva possesses the world's most extensive generic pharmaceutical manufacturing infrastructure, with 48 facilities producing 76 billion doses annually — a scale-based competitive moat that would require tens of billions in capital to replicate. Second, its vertically integrated API manufacturing capabilities provide cost and supply chain advantages that outsourced competitors cannot match. Third, the innovative branded portfolio has successfully transitioned from a drag on earnings to a growth engine, with Austedo alone generating over USD 2.2 billion in 2025. Fourth, the geographically diversified manufacturing footprint across Europe and North America mitigates the operational risks associated with its Israeli headquarters. Fifth, Teva's products are essential to the functioning of public healthcare systems globally, providing recession-resistant demand characteristics.

Challenges & Outlook

Teva's primary risk factor remains the geopolitical instability in Israel, where a significant portion of its R&D and management functions are concentrated. The company has proactively diversified manufacturing across Europe and North America to ensure supply continuity. Generic drug pricing continues to face government-mandated reductions in key markets including the United States and Japan. However, the accelerating growth of the innovative portfolio and the company's successful debt reduction trajectory position Teva for sustained value creation. The 2026 guidance of USD 16.4-16.8 billion in revenue with over USD 2 billion in free cash flow signals management's confidence in the ongoing recovery.

VerityRank Score

Teva Pharmaceutical Industries achieves a VerityRank Score of 85/100, reflecting its market leadership, revenue scale, R&D capabilities, global manufacturing footprint, and competitive positioning within the pharmaceutical industry.